Illumina, Inc. (NASDAQ:ILMN) has received an average rating of “Hold” from the twenty-three brokerages that are currently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a sell rating, ten have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $161.91.

Several brokerages have weighed in on ILMN. Vetr upgraded Illumina from a “buy” rating to a “strong-buy” rating and set a $196.75 target price on the stock in a research note on Monday, April 24th. Canaccord Genuity restated a “hold” rating and issued a $150.00 price target on shares of Illumina in a research note on Tuesday, February 21st. Leerink Swann upgraded Illumina from a “market perform” rating to an “outperform” rating and set a $195.00 price target on the stock in a research note on Monday, March 20th. BTIG Research restated a “hold” rating on shares of Illumina in a research note on Sunday, March 19th. Finally, Evercore ISI upgraded Illumina from a “hold” rating to a “buy” rating and set a $190.00 price target on the stock in a research note on Monday, February 27th.

COPYRIGHT VIOLATION WARNING: This story was first reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/06/16/illumina-inc-ilmn-receives-consensus-recommendation-of-hold-from-analysts.html.

Shares of Illumina (NASDAQ:ILMN) traded down 0.24% during midday trading on Friday, reaching $171.63. The company had a trading volume of 621,672 shares. Illumina has a 52-week low of $119.37 and a 52-week high of $189.48. The stock has a market capitalization of $25.06 billion, a PE ratio of 34.74 and a beta of 0.76. The company’s 50 day moving average price is $179.36 and its 200 day moving average price is $162.09.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, April 25th. The life sciences company reported $0.64 earnings per share for the quarter, meeting the consensus estimate of $0.64. Illumina had a return on equity of 21.21% and a net margin of 30.75%. The company had revenue of $598 million for the quarter, compared to the consensus estimate of $590.51 million. During the same period last year, the business posted $0.71 EPS. The company’s revenue was up 4.5% on a year-over-year basis. Equities research analysts expect that Illumina will post $3.63 earnings per share for the current year.

In related news, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction on Tuesday, May 9th. The stock was sold at an average price of $184.14, for a total value of $3,682,800.00. Following the completion of the transaction, the director now directly owns 539,176 shares in the company, valued at $99,283,868.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Marc Stapley sold 2,000 shares of the company’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $170.85, for a total value of $341,700.00. Following the completion of the transaction, the executive vice president now owns 41,341 shares of the company’s stock, valued at $7,063,109.85. The disclosure for this sale can be found here. Over the last three months, insiders sold 77,057 shares of company stock valued at $13,859,634. Insiders own 1.60% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the stock. Patten Group Inc. raised its position in Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after buying an additional 25 shares during the last quarter. Forte Capital LLC ADV raised its position in Illumina by 1.6% in the first quarter. Forte Capital LLC ADV now owns 2,185 shares of the life sciences company’s stock valued at $373,000 after buying an additional 35 shares during the last quarter. Gemmer Asset Management LLC raised its position in Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock valued at $117,000 after buying an additional 37 shares during the last quarter. Bronfman E.L. Rothschild L.P. raised its position in Illumina by 3.6% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 1,198 shares of the life sciences company’s stock valued at $204,000 after buying an additional 42 shares during the last quarter. Finally, Cleararc Capital Inc. raised its position in Illumina by 1.3% in the first quarter. Cleararc Capital Inc. now owns 3,326 shares of the life sciences company’s stock valued at $568,000 after buying an additional 44 shares during the last quarter. Hedge funds and other institutional investors own 96.85% of the company’s stock.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.